Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Andrew McConaghie
Gene Profiling Identifies Drugs For Childhood Cancers But Access A Problem
Lack of infrastructure for identifying mutations and access routes is holding back use of targeted medicines in children with cancer
ESMO Preview: Five Key Oncology Battlegrounds To Watch
GSK looks to become a cancer contender once again, while Merck and Roche go toe-to-toe in TNBC.
Breakthrough Designation Confirms Gazyva Promise In Lupus Nephritis
Promising Phase II data mean it could be third time lucky for Roche in disease with no approved treatments.
Roche: We’ve Abandoned Budgets And It’s Liberated Employees
Bill Anderson says Roche has scrapped budgets and improved productivity and re-energised teams. But is it too good to be true?
Bucking Biosimilar Threat, Roche Sees Further Growth
Many new and pipeline products were highlighted at London meeting – but no word on Spark Therapeutics deal. New products will have high profit margins.
Investigating Big Pharma Licensing Trends
AstraZeneca emerged as big pharma’s most active dealmaker over the 2014-2018 period, thanks to a combined surge in both in-licensing and out-licensing agreements.